Fourth Circuit Rejects Whistleblower Action Against Drug Maker Alleging Medicaid Rebate Program Fraud
- January 28, 2022
A qui tam relator could not plausibly allege that Forest Laboratories (Forest), a subsidiary of Allergan plc, made false statements with the requisite knowledge to violate the False Claims Act (FCA) because its interpretation of ambiguous Medicaid Drug Rebate Program requirements was at the very least objectively reasonable, the Fourth Circuit held January 25.
ARTICLE TAGS
You must be logged in to access this content.